An Expanded Access IND for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NO_LONGER_AVAILABLE

Conditions studied: Chronic Inflammatory Demyelinating Polyneuropathy

In brief

This is an Individual Patient Expanded Access IND to evaluate the safety and preliminary efficacy of autologous HB-adMSCs for treating a single patient Chronic Inflammatory Demyelinating Polyneuropathy, CIDP. The expanded access program will include a screening period of up to 28 days, a 44-week treatment period, a safety follow-up at 50, and a 52-week end-of-study visit.

Key facts

Study ID

NCT04825626

Run by

Hope Biosciences Research Foundation

Last updated by the study team

2025-09-29

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Hope Biosciences Stem Cell Research Foundation — Sugar Land, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.